Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk by Brænne, I. (Ingrid) et al.
RESEARCH ARTICLE
Genomic correlates of glatiramer acetate
adverse cardiovascular effects lead to a novel
locus mediating coronary risk
Ingrid Brænne1,2,3, Lingyao Zeng4, Christina Willenborg1, Vinicius Tragante5,
Thorsten Kessler4, CARDIoGRAM Consortium¶, CARDIoGRAMplusC4D Consortium¶,
Cristen J. Willer6, Markku Laakso7, Lars Wallentin8, Paul W. Franks9, Veikko Salomaa10,
Abbas Dehghan11, Thomas Meitinger12,13,14, Nilesh J. Samani15, Folkert
W. Asselbergs5,16,17, Jeanette Erdmann1,2,3*, Heribert Schunkert4,13
1 Institute for Cardiogenetics, University of Lu¨beck, Lu¨beck, Germany, 2 DZHK (German Research Center
for Cardiovascular Research), partner site Hamburg/Lu¨beck/Kiel, Lu¨beck, Germany, 3 University Heart
Center Lu¨beck, Lu¨beck, Germany, 4 Deutsches Herzzentrum Mu¨nchen, Technische Universita¨t Mu¨nchen,
Mu¨nchen, Germany, 5 Department of Cardiology, Division Heart and Lungs, UMC Utrecht, Utrecht, The
Netherlands, 6 University of Michigan, Dept of Biostatistics, 1415 Washington Hts, Ann Arbor, MI, United
States of America, 7 Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and
Kuopio University Hospital, Kuopio, Finland, 8 Uppsala Clinical Research Center, Uppsala Science Park,
MTC, Uppsala, Sweden, 9 Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund
University, Skåne University Hospital Malmo¨, Malmo¨, Sweden, 10 THL-National Institute for Health and
Welfare, POB 30, Mannerheimintie 166, Helsinki, Finland, 11 Department of Epidemiology, Erasmus
University Medical Center, CA Rotterdam, The Netherlands, 12 Institute of Human Genetics, Helmholtz
Zentrum Mu¨nchen, German Research Center for Environmental Health, Neuherberg, Germany, 13 DZHK
(German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany,
14 Institute of Human Genetics, Technische Universita¨t Mu¨nchen, Munich, Germany, 15 Department of
Cardiovascular Sciences University of Leicester and NIHR Leicester Cardiovascular Biomedical Research
Unit, Glenfield Hospital, Leicester, United Kingdom, 16 Durrer Center for Cardiovascular Research,
Netherlands Heart Institute, Utrecht, the Netherlands, 17 Institute of Cardiovascular Science, faculty of
Population Health Sciences, University College London, London, United Kingdom
¶ The memberships of CARDIoGRAM and CARDIoGRAMplusC4D consortia are provided in the
Acknowledgments.
* jeanette.erdmann@uni-luebeck.de
Abstract
Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse
effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying
the cardiovascular side effects of the medication are unclear. Here, we made use of the
chromosomal variation in the genes that are known to be affected by glatiramer treatment.
Focusing on genes and gene products reported by drug-gene interaction database to in-
teract with glatiramer acetate we explored a large meta-analysis on CAD genome-wide
association studies aiming firstly, to investigate whether variants in these genes also affect
cardiovascular risk and secondly, to identify new CAD risk genes. We traced association
signals in a 200-kb region around genomic positions of genes interacting with glatiramer in
up to 60 801 CAD cases and 123 504 controls. We validated the identified association in
additional 21 934 CAD cases and 76 087 controls. We identified three new CAD risk alleles
within the TGFB1 region on chromosome 19 that independently affect CAD risk. The lead
SNP rs12459996 was genome-wide significantly associated with CAD in the extended
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meta-analysis (odds ratio 1.09, p = 1.58×10−12). The other two SNPs at the locus were not
in linkage disequilibrium with the lead SNP and by a conditional analysis showed p-values of
4.05 × 10−10 and 2.21 × 10−6. Thus, studying genes reported to interact with glatiramer ace-
tate we identified genetic variants that concordantly with the drug increase the risk of CAD.
Of these, TGFB1 displayed signal for association. Indeed, the gene has been associated
with CAD previously in both in vivo and in vitro studies. Here we establish genome-wide sig-
nificant association with CAD in large human samples.
Introduction
Glatiramer acetate (GA), also known under the trade name Copaxone1, is an immunomodu-
lator used in the treatment of relapsing-remitting multiple sclerosis (MS). It is a synthetic pep-
tide consisting of four amino acids[1, 2]. GA is assumed to bind major histocompatibility
complex (MHC) molecules and compete with various myelin antigens[2]. This competitive
binding affects the presentation of myelin antigens to T-cells. In addition, GA potentially pro-
motes suppressor T-cells[1, 3]. A further mechanism of action is that GA-induced T helper
cells secrete high amounts of cytokines such as IL-4/10 and TGF-β[2]. In mice, GA is reported
to induce transforming growth factor β 1 (TGFB1) in several cell types such as monocytes[4],
Th2/3 cells[5] and brain[6]. In addition, it is known that polymorphisms in the TGFB1 gene
alter the GA treatment response[7].
According to the FDA,drugs.com and the copaxone own webpage (copaxone.com), GA is
reported to induce hypertension and increase the risk of coronary artery disease (CAD) and
myocardial infarction. The exact mechanisms that explain the increased risk of CAD or hyper-
tension under GA treatment are, however, not fully understood.
Understanding the genetic mechanisms underlying a disease can facilitate the identification
of new drug targets. Indeed, several drugs have been developed based on genetic findings [8–
10]. Moreover, if we know which genes or pathways are targeted by a drug, we may also predict
adverse effects based on variants in these genes modulating risk[11, 12]. Here, we reversed this
approach to identify new disease risk genes. We screened genes that are reported to interact
with a drug that increases the risk of CAD to identify new CAD risk alleles. In a previous
study, we identified new CAD risk genes by studying the pleiotropic effects of cyclooxygenase
2 inhibitors[13].
In this work, we first identified genes and gene products reported to interact with GA.
These genes were then screened for association in the largest meta-analysis on CAD genome-
wide association studies (GWAS), CARDIoGRAMplusC4D 1000G[14]. The underlying idea is
that single nucleotide polymorphisms (SNPs) in cis with these genes may affect expression or
structure of these genes in a similar way as the drug. Hence, we expect that some of these SNPs
also may increase the risk of CAD, even though the effect size might vary between drug and
variant.
Methods
The first step of the analysis was to identify genes or gene products reported to interact with
GA. For this, we used the Drug Gene Interaction Database (DGIdb)[15]. Second, in a large
CAD GWAS dataset, we identified all SNPs within 200kb surrounding the four genes identi-
fied in the first step of this analysis. The 200kb window was selected to also include regulatory
SNPs affecting gene expression.
Genomic correlates of GA adverse effects lead to a novel CAD locus
PLOS ONE | https://doi.org/10.1371/journal.pone.0182999 August 22, 2017 2 / 19
01ZX1306A), and the European Union Seventh
Framework Programme FP7/2007-2013 under
grant agreement no HEALTH-F2-2013-601456
(CVgenes-at-target). Further grants were
received from the DFG as part of the
Sonderforschungsbereich CRC 1123 (B2).
T.K. was supported by a DZHK Rotation
Grant. I.B. was supported by the Deutsche
Forschungsgemeinschaft (DFG) cluster of
excellence ‘Inflammation at Interfaces’. F.W.A.
is supported by a Dekker scholarship-Junior
Staff Member 2014T001 – Netherlands Heart
Foundation and UCL Hospitals NIHR Biomedical
Research Centre. This work was supported by the
German Research Foundation (DFG) and the
Technical University of Munich within the funding
programme Open Access Publishing.
Competing interests: P.W.F. reports grants from
Sanofi Aventis, grants from Lilly, grants from Novo
nordisk, personal fees from Sanofi Aventis,
personal fees from Lilly. L.W. reports institutional
research grants, consultancy fees, lecture fees, and
travel support from AstraZeneca, institutional
research grants, consultancy fees, lecture fees, and
travel support from Boehringer Ingelheim,
institutional research grants, consultancy fees,
lecture fees, and travel support from Bristol-Myers
Squibb/Pfizer, grants from Merck & Co, grants
from Roche, consultancy fees from Abbott and
holds two patents involving GDF-15. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials.
GWAS dataset
The CARDIoGRAMplusC4D 1000Genomes meta-analysis data set consists of 47 GWAS stud-
ies including 60 801 CAD cases and 123 504 controls. Ethical approval was obtained from the
appropriate ethics committees and informed consent was obtained from all participants. Spe-
cifically, the studies involving genome-wide SNP analysis for CAD were approved by the ethics
commissions of the University of Regensburg (02/042), the University of Lu¨beck (04/041) und
the Technical University of Munich (406/15s). The GWAS are imputed with the December
2012 1000Genomes phase I integrated haplotypes (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
release/20110521/) (for Methods see Nikpay et al.[14]).
We validated and later combined the CARDIoGRAMplusC4D 1000Genomes meta-analysis
data set[14] with GWAS data from CHARGE, deCODE CAD, DILGOM, EPIC, FRISC II
GLACIER, METISM, MORGAM FIN, MORGAM FRA, MORGAM GER, MORGAM ITA,
MORGAM UNK, PMB, PopGen, SCARF SHEEP, and STR that have been previously reported
in references Schunkert et al. [16] and/or Deloukas et at. [17]. Moreover, we included data
from GWAS not reported before, i.e. German MI Family Studies V. See detailed information
in S1 Table. In total, this combined dataset consists of 82 735 cases and 199 591 controls. Com-
pared to the CARDIoGRAMplusC4D study, we increase the sample size by 21.934 cases and
76.087 controls.
Meta-analysis
Logistic regression, assuming an additive model, was performed on all single study data. All
analyses were adjusted for sex and age. Age was defined as the recruitment age for controls
and the event age for cases. We used the fixed-effect inverse variance-weighted meta-analysis
to combine single analyses data. Quality control was performed at individual sites and centrally
to assure standardized data formats previously agreed criteria including check of consistency
of the given alleles across all studies, quality of the imputation, deviation from Hardy-Wein-
berg equilibrium and call rate. If individuals or single studies did not pass quality control, they
were excluded. SNPs were also excluded from the meta-analysis if present in less than 17
GWAS.
For the meta-analysis, we calculated an ’inverse variance weighting’- fixed-effects and a ran-
dom effects model[18], depending on the heterogeneity between the studies. For heterogeneity
calculation, Cochran’s Q was used. The threshold for heterogeneity was phet<0.01. For the
combination of the stages (stage1: results of 1000G meta-analysis; stage 2: replication in CAR-
DIoGRAM, CARDIoGRAMplusC4D, GerMIFS V) an ’inverse variance weighting’- the fixed-
effects model was calculated and the combined effects and p-values were reported. In total, we
evaluated the genomic data from 82 735 cases and 199 591 controls.
Statistical methods
The number of SNPs tested in the initial screen (for the four genes) is 20,027. We corrected
the p-value threshold based on the number of SNPs tested using the Bonferroni correction.
Hence, all SNPs with p-values below 2.5x10-6 were considered significant.
Identification of TGFB1 sub-loci
We used Haploreg version 4.1[19] with the European 1000G Phase 1 database for LD calcula-
tion. We identified LD blocks based on LD> 0.4 to the lead SNPs. In detail, we repeated the
following three steps until no sub-loci with a p-value below 1×10−6 were found.
1. Identification of current lead SNP (SNP with the lowest p-value).
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2. Identify all SNPs in LD (r2>0.4) with the current lead SNP.
3. Remove lead and LD SNPs from dataset
To test for independence between the identified sub-loci, we performed conditional analy-
sis using summary statistic data with the GCTA tool[20]. As reference data used the GerMIFs
II study. For conditional analysis, we used the SNPs identified in the above-described sub-loci
analysis. We first performed a joint analysis using the–cojo-joint option and then performed
the conditional analysis (—cojo-cond) based on the independent SNPs identified in the joint
analysis step.
Functional annotation of SNPs and TGFB1
To evaluate the functional implication of the SNPs, we identified all SNPs in high LD (r2>0.8)
with the locus lead SNP using the HaploReg version 4.1 database[19]. To estimate the effect of
a SNP on gene expression, we identified expression quantitative trait loci (eQTLs) using the
publicly available data from Westra et al.[21], GTeX[22] as well as over 100 studies included in
the Genome-Wide Repository of Associations between SNPs and Phenotypes (GRASP) data-
base[23]. In addition, we used HaploReg and RegulomeDB[24] to functionally annotate SNPs
and performed a literature search for gene functions using Pubmed.
Results
The principle idea of this approach is illustrated in Fig 1. Using DGIdb[15], we identified four
genes reported to interact with GA; CCR5, HLA-DRB1, IFNAR1, and TGFB1. Of these, only
the TGFB1 region displayed signals suggesting an association with CAD risk (Fig 2). We
Fig 1. Schematic approach. 1) Identification of reported adverse effect of GA 2) Identify genes reported to interact with GA. 3) Establish a link between the
genes identified in 2. and the adverse effect identified in 1).
https://doi.org/10.1371/journal.pone.0182999.g001
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validated the GA-TGFB1 interaction performing a literature search[2, 4–6]. Moreover, from a
mechanistic point of view, TGFB1 is the only gene with evidence of a functional association
with CAD (see S1 Fig). Hence, we did not examine the other genes further.
In our first GWAS look-up, the lead SNP, rs15052, close to TGFB1 yielded a p-value of
2.21 × 10−7. In a replication study with independent samples, rs15052 showed a p-value of
9.97 × 10−4, hence validating the initial finding. We next combined the data sets and reran the
analysis. In this combined meta-analysis, rs15052 yielded a genome-wide significant p-value of
9.11 × 10−10. The new lead SNP in the joint meta-analysis, rs12459996 had a p-value of
1.58 × 10−12 and an OR of 1.09 (see Fig 3).
The TGFB1 locus presumably harbors several independent sub-loci (see Table 1). Using the
GCTA conditional analysis on summary statistic data, we identified three such independent
signals. In addition to the genome-wide significant lead SNP, two sub-loci show significant
p-values (rs1056854: 3.30 × 10−7 and rs75041078: 3.87 × 10−7). We conditioned the two new
SNPs on rs12459996 in a stepwise approach. rs1056854 showed the lowest p-value after con-
ditioning with rs12459996 with a p-value of 4.07x10-10 and an OR of 1.07. Conditioning
rs75041078 on the lead SNPs rs12459996 and rs1056854, we get a p-value for the third SNP of
2.21x10-6 with an OR of 1.05.
Fig 2. GA interacts with CCR, TGFB1, IFNAR1 and HLA-DRB1 (solid line). Moreover, it is known that GA affects CAD (Coronary Artery Disease)
risk (dashed line). In this work, we searched for SNPs associated with CAD in the gene regions representing the GA off target effects (dotted lines).
We found a genome-wide significant association for the TGFB1 locus with a p-value of 1.58 × 10−12 (red dotted line). n.s.: non-significant; TGFB1:
Transforming Growth Factor, Beta 1; CCR5: Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene); IFNAR1: Interferon (Alpha, Beta And Omega)
Receptor 1; HLA-DRB1: Major Histocompatibility Complex, Class II, DR Beta 1.
https://doi.org/10.1371/journal.pone.0182999.g002
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Fig 3. Association sub-loci signal for the TGFB1 locus. The three lead SNPs are shown with the corresponding high-LD blocks (SNPs within
r2>0.2.) depicted in orange, red and green. Independent sub-loci were identified with the GCTA conditional analysis tool (see methods). The LD
between the lead SNPs indicated and under r2<0.1. The three individual LocusZoom plots are found in the S2 Fig.
https://doi.org/10.1371/journal.pone.0182999.g003
Table 1. TGFB1 locus.
Sub-
locus
Lead SNP CAD
risk
allele
Frequency
risk allele
OR (CI)
risk
allele
P-value
combined
analysis
P-value joint
analysis
GCTA
OR risk allele
joint analysis
GCTA
SNP effect
on TGFB1
Regulatory
function
Haploreg
Regulatory
function
Regulome
score
I rs12459996 T 0.10 1.09
(1.06–
1.12)
1.58x10-12 2.73x10-9 1.09 Increased
expression
enhancer 6
II rs75041078 A 0.25 1.06
(1.04–
1.09)
3.87x10-7 4.05x10-10 1.07 n/a enhancer n/a
III rs1056854 A 0.86 1.06
(1.04–
1.08)
3.30x10-7 2.21x10-6 1.05 increased
expression
enhancer 5
https://doi.org/10.1371/journal.pone.0182999.t001
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To evaluate the functional implication of the three potentially independent associations, we
performed an in-silico evaluation of the lead SNPs and the SNPs in high LD with these (r2 >
0.8) (see S2 Table for detailed results).
The genome-wide significant lead SNP rs12459996 (p = 1.58 × 10−12; OR = 1.09), is found
in a regulatory region and is marked as a strong promoter and enhancer in several cell types
including smooth muscle and T-helper cells. As the promoter marks are downstream TGFB1,
it is more likely that the regulatory effect on TGFB1 is acting through the enhancer. The lead
SNP and SNPs in high LD (r2>0.8) are reported to have an eQTL effect on TGFB1 in the thy-
roid gland (p = 3.0 × 10−8, OR = 1.58) and the skeletal muscle (p = 5.6 × 10−6, 1.36) (GTEX).
The CAD risk allele T is associated with increased TGFB1 expression in both cell types.
The second sub-locus has the lead SNP rs75041078 (conditional p = 4.07x10-10, conditional
OR = 1.07). This SNP is not in high LD with any other SNP (r2>0.8). It is located in the intron
of TMEM91 and lies in an enhancer histone mark in neutrophils. We did not find any eQTL
effect in the databases searched.
The third sub-locus, with the lead SNP rs1056854 (conditional p = 2.21x10-6, conditional
OR = 1.05), is also located in a regulatory region, which includes a promoter histone mark in
various cell types, including H1-hESC cells. The locus is, however, downstream or rather at
the 30 end of the TGFB1 gene and hence the promoter unlikely to affect the TGFB1 gene. SNPs
in high LD are also found in enhancer histone marks in multiple cell types, including T cells,
T-helper cells and monocytes. Hence, the locus might have a regulatory effect on TGFB1.
Supporting this hypothesis, we identified an eQTL effect on TGFB1 in the adrenal gland, sug-
gesting a link between the SNP and the gene also in other tissues. The CAD risk allele A is asso-
ciated with increased expression of TGFB1 (p = 1.510−6, OR = 2.2).
Discussion
Exploring drug-gene interactions, we identified four genes or gene products to be affected by
glatiramer acetate, a drug known to increase the risk of severe coronary events. Analyzing the
genomic loci harboring these genes, we identified TGFB1 as a new genome-wide significant
locus displaying association for CAD. The results of this analysis give rise to the hypothesis
that the known interaction of GA with TGFB1 may be responsible for modulating the risk of
CAD. Indeed, the results point towards a novel mechanism for the increased risk of CAD
under GA treatment.
The pharmacologic mechanisms of GA in the treatment of multiple sclerosis are not fully
understood. The general assumption is that the immune-modulatory activity of GA is related
to the change of the T-cell antigen reactivity. Through its presumed binding to the MHC class
II, GA is thought to alter the presentation of myelin antigens to auto-reactive T-cells and
thereby affects the activity of the antigen presenting cells[25]. It is also known that GA induces
the secretion of cytokines such as IL-4/10 and TGF-β in T-helper cells[2], which according to
the present data may affect the risk of CAD under GA treatment.
TGFB1 (transforming growth factor, beta1) is a multifunctional peptide controlling multi-
ple cellular functions such as proliferation and differentiation in several cell types. It plays an
important role in the pathophysiology of the endothelial and vascular smooth muscle cell.
TGFB1 is a very likely CAD candidate gene and has been linked to a range of cardiovascular
traits such atherosclerosis, hypertension, inflammation and aneurysm [26–29]. TGFB1 serum
levels are also reported to be higher in CAD patients[30]. In addition, several variants within
other genes in the TGFB–SMAD signaling pathway have been associated with CAD[26, 29,
31–34]. It is, hence, also possible, that GAs interaction with TGFB1 influences other reported
adverse effects such as the increased risk of hypertension. We cannot exclude that the GA
Genomic correlates of GA adverse effects lead to a novel CAD locus
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related risk of CAD is secondary to GA induced hypertension, but at the same time we can
also not exclude other pathways. TGFB1 is involved in multiple cellular functions suggesting
increased CAD risk through multiple pathways.
Here, we identified three independent CAD associated signals within the TGFB1 locus. The
TGFB1 locus has not been genome-wide significantly associated with CAD before, most likely
due to small effect sizes and hence insufficient power of previous studies. The three variants
are not associated with CAD related traits based on a GRASP database search (p<1x10-4).
However, the overlap of the locus with immune cell histone marks suggest a link to inflamma-
tion. The lead SNP (rs12459996) of the TGFB1 locus is reported to increase the expression of
the gene, which matches with the direction of effect reported for GA. In addition, the risk allele
of the sub-locus rs1056854 is also associated with increased expression of the gene. The identi-
fied TGFB1 locus is also associated with expression of other genes (CCDC97, HNRNPUL1,
AXL, BCKDHA) (see S2 Table). Because our study focused on genes that interact with GA, we
did not discuss these genes at this locus. It is however possible, that these genes influence the
risk of CAD as well. Indeed, several studies have demonstrated that a regulatory SNPs have
effects on more than one gene. In a previous study, we found multiple genes per locus where
either all SNPs, a subset or only one SNP increase the risk of CAD[35].
The molecular effects of TGFB have been extensively studied in vitro and in vivo models
linking the gene to CAD risk. For example, TGFB1 has been associated with several CAD
related phenotypes such as thrombosis, inflammation, hypertension and neointima growth
[36–44]. However, the net effect of TGFB may vary. Indeed, TGFB1 may either increase or
decrease inflammation, activate or deactivate macrophages, depending on the local cytokine
environment[29]. This is mainly due to the fact that it acts through several signaling pathways
affecting several CAD related phenotypes with partially opposing effect on risk [29, 33]. In
early stages of the disease, TGFB1 may be atheroprotective and higher levels of TGFB1 have
been reported to decrease the risk of atherosclerosis[29]. In fact, TGFB1 displayed dosage
effects where lower levels of TGFB1 increased proliferation whereas higher levels inhibited
proliferation in endothelial cells[36]. Vice versa, in the presence of disease increased TGFB1
signaling has been associated with increased restenosis by increasing neointima growth[37,
38]. Moreover, TGFB1 has been linked to accelerated thrombus formation by inducing platelet
aggregation [39, 40] and the expression is increased in rats with traumatic deep vein thrombo-
sis versus control rats [41]. TGFB1 was also found to inhibit nitric oxide in vascular endothelial
cells linking higher levels of TGFB1 to increased blood pressure[42, 43]. In addition, TGFB1
expression was also reported to be increased in patients with hypertension[44].
Our study design has several limitations. Our findings are based on associations rather than
on functional testing. We thus cannot infer the precise pathway that is affected by the genetic
variants at the TGFB1 locus. However, functional effects of the risk allele on expression levels
have been previously reported and go in the same direction of TGFB1 expression as the effects
reported in the literature for GA. Moreover, the association between the TGFB1 locus and
CAD risk reaches genome-wide significance, which can be regarded as a conclusive and scien-
tifically important observation independently of the overlap with GA side effects including
enhanced TGFB1 expression. Indeed, the links reported here, first between GA and CAD risk
(drugs.com), second between GA and TGFB1[2] and third the genome-wide significant associ-
ation of TGFB1 SNPs with CAD are each highly conclusive. Together they allow hypothesizing
that TGFB1 is involved in the increased risk of CAD under GA treatment.
Taken together, our results imply mechanistic similarities between pharmacologic
responses to GA treatment and genetic variants affecting CAD risk. While GA treatment is
known to enhance TGFB1 expression and CAD risk, we here associate SNPs within the
TGFB1 locus linked with CAD risk and enhanced TGFB1 expression. Thus, both the newly
Genomic correlates of GA adverse effects lead to a novel CAD locus
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identified CAD risk alleles and GA appear to induce the expression of TGFB1, suggesting that
the CAD risk alleles and the drug have similar effects on the gene product and subsequently on
CAD risk. With an additive effect, the CAD risk alleles might also explain variable CAD risk
under GA treatment. Finally, in this study, we identified TGFB1 as a new genome-wide signifi-
cant locus affecting CAD risk.
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